Without “decisive action” cancer deaths across the European Union (EU) will increase by almost a quarter by 2035, making it the bloc’s leading cause of death.
Expediating access to new treatments is key to avoiding this devastating outcome, according to a new publication from the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Every Day Counts: Improving Regulatory Timelines to Optimise Patient Access to Innovative Oncology Therapies in Europe says optimising regulatory pathways is not only desirable, but, as the global response to COVID-19 has shown, it is possible.
